S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
Log in
NASDAQ:SPRO

Spero Therapeutics Stock Forecast, Price & News

$17.99
-0.67 (-3.59 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.76
Now: $17.99
$19.05
50-Day Range
$16.08
MA: $18.29
$22.07
52-Week Range
$5.25
Now: $17.99
$23.64
Volume203,284 shs
Average Volume299,534 shs
Market Capitalization$489.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics logo

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

391st out of 1,926 stocks

Pharmaceutical Preparations Industry

206th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600
Employees57
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.15 million
Book Value$3.90 per share

Profitability

Net Income$-60,920,000.00
Net Margins-768.15%

Miscellaneous

Market Cap$489.09 million
Next Earnings Date3/15/2021 (Estimated)
OptionableOptionable
$17.99
-0.67 (-3.59 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

How has Spero Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SPRO stock has increased by 132.1% and is now trading at $17.99.
View which stocks have been most impacted by COVID-19
.

Is Spero Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spero Therapeutics stock.
View analyst ratings for Spero Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Spero Therapeutics?

Wall Street analysts have given Spero Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Spero Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Spero Therapeutics
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.05. The firm earned $4 million during the quarter, compared to the consensus estimate of $2.28 million. Spero Therapeutics had a negative net margin of 768.15% and a negative trailing twelve-month return on equity of 93.43%.
View Spero Therapeutics' earnings history
.

What price target have analysts set for SPRO?

6 brokers have issued twelve-month price targets for Spero Therapeutics' shares. Their forecasts range from $19.00 to $47.00. On average, they anticipate Spero Therapeutics' stock price to reach $32.75 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price.
View analysts' price targets for Spero Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Spero Therapeutics' key competitors?

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:
  • Dr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 39, Pay $747.88k)
  • Ms. Cristina Larkin, Chief Operating Officer (Age 50, Pay $552.96k)
  • Dr. David A. Melnick M.D., Chief Medical Officer (Age 68, Pay $545.96k)
  • Mr. Stephen J. DiPalma M.B.A., Interim CFO & Treasurer (Age 61)
  • Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 66)
  • Ms. Sharon Klahre, VP of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M., J.D., Chief Legal Officer (Age 57)
  • Mr. Jay Blackington, VP of People Strategy & Culture
  • Mr. Timothy Keutzer, Chief Devel. Officer (Age 52)
  • Dr. Ian A. Critchley, Head of Clinical Microbiology

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Gofen & Glossberg LLC IL (0.06%) and Janney Montgomery Scott LLC (0.04%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics
.

Which institutional investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Aquilo Capital Management, Llc, and Cristina Larkin.
View insider buying and selling activity for Spero Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Spero Therapeutics stock?

SPRO stock was acquired by a variety of institutional investors in the last quarter, including Gofen & Glossberg LLC IL.
View insider buying and selling activity for Spero Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $17.99.

How big of a company is Spero Therapeutics?

Spero Therapeutics has a market capitalization of $489.09 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 57 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.